What is the pipeline for future medications for obesity?

What is the pipeline for future medications for obesity? - Nature

In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based ...

What is the pipeline for future medications for obesity? - PubMed

Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight ...

A look at the R&D landscape in obesity, led by GLP-1s - Fierce Biotech

Industry data provider IQVIA pulled together a list of the current obesity pipeline, which features 124 medicines altogether: 61 in phase 1, 47 ...

What Drugs Are Being Researched for Obesity?

Orforglipron is a GLP-1 agonist. It's an oral version of the injectable drug semaglutide that helps improve weight loss in adults with obesity.

What is the pipeline for future medications for obesity? - ResearchGate

In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based ...

What does the future hold for obesity medication development?

Semaglutide is a GLP-1 RA drug that received approval in 2021 for obesity management. This drug promotes around 17% weight loss through a ...

Future therapies for obesity - PMC

Oral semaglutide is approved for T2DM at doses up to 14 mg once daily and provides an additional option for people reluctant to initiate injectable treatments.

Obesity: Six trials to watch over the next 12 months

The Phase IIb trial of danuglipron tromethamine is due to end on 12 September 2023. The trial is evaluating the efficacy and safety of the drug ...

4 Investigational Weight Loss Drugs That Could Change the Market

GLP-1 treatments are all the rage in this space, but they aren't the only approach in development. The pipeline assets highlighted here ...

an update on the available medications and drugs under investigation

Metreleptin and Setmelanotide are currently indicated for rare obesity syndromes, and 5 other medications (orlistat, phentermine/topiramate, naltrexone/ ...

When the dust settles: The future shape of the obesity market - IQVIA

A crowded pipeline: The stellar performance of Novo Nordisk's and Lilly's respective obesity franchises has prompted many companies to pursue ...

16 New Weight Loss Drugs - GoodRx

Researchers are studying several weight-loss pills in clinical trials. Medications such as oral semaglutide, orforglipron, and amycretin have notable ...

Beyond Ozempic: New GLP-1 drugs promise weight loss and health ...

More drugs in the pipeline ... Eli Lilly, which makes Zepbound and the diabetes version Mounjaro, has two more GLP-1 drugs in development. On ...

Oral obesity therapies: Holding the key to the future - IQVIA

Ensuring affordability by patients, in out-of-pocket markets, and by health systems to expand reimbursement of weight loss medicines to ensure ...

Anti-obesity drug development: Industry trends in 2024 | Gubra

Recent FDA Approvals and Advances in Anti-obesity Drugs · Breakthrough Treatments: Semaglutide and Tirzepatide · Comparative Efficacy: Semaglutide ...

Biotechs ride obesity drug wave with novel approaches that go ...

Several catalytic events for novel obesity pipeline drugs that go beyond targeting GLP-1 receptors are expected this year. Table with 7 columns ...

Transforming obesity: The advancement of multi-receptor drugs: Cell

For more than a century, physicians have searched for ways to pharmacologically reduce excess body fat. The tide has finally turned with ...

Breakthrough obesity treatments on the horizon, rivaling surgery's ...

However, oral RAs are being developed to increase acceptance and adherence. Besides, a pipeline of pharmacotherapies based on entero-pancreatic ...

Beyond Semaglutide, a Coming Pipeline of New Antiobesity Meds

With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, ...

Obesity Clinical Trial Pipeline Appears Robust With 80+ Key

DelveInsight's 'Obesity Pipeline Insight 2024' report provides comprehensive global coverage of pipeline obesity therapies in various stages of clinical ...